logo
Share SHARE
FONT-SIZE Plus   Neg

Varonis Systems Files For $100 Mln IPO - Quick Facts

Varonis Systems, Monday said it has filed for an Initial Public Offering of $100 million with the Securities Exchange Commission. The company will not receive any proceeds from the sale of shares by the selling stockholders. Varonis plans to list the common stock on The Nasdaq Global Select Market under the symbol "VRNS."

For the nine-month period ended September 30, the company had reported a loss of $8.9 million or $2.32 per share, on revenues of $48.9 million.

Varonis Systems was founded by networking and storage experts Yaki Faitelson and Ohad Korkus. Varonis is a solution provider of comprehensive, actionable data governance solutions for unstructured and semi-structured data with over 4500 installations spanning leading firms in financial services, government, healthcare, energy, media, education, manufacturing and technology worldwide.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of International Consolidated Airlines Group S.A. were gaining around 3 percent in London trading after the airline reported Friday higher profit in its second quarter, benefited by higher passenger revenues, despite weak cargo revenues. The company now expects low double digit percentage growth in pre-exceptional operating profit in 2016. Swiss banking giant UBS Group AG reported Friday a 14 percent decline in second quarter profit with weakness in net interest income. Looking ahead, the company said the difficult conditions continue to persist, yet the firm is well positioned to benefit from even a moderate improvement in conditions. UBS shares were gaining around 3 percent in the morning trading in Zurich. We are well into the third quarter and past the middle of the year and it is time to take stock of regulatory decisions awaiting some biotech stocks in August. Despite the uncertain macroeconomic environment, the markets have run up, with the S&P 500 Index making new highs session after session. Valuation concerns may keep traders at bay. However, the biotech space is a different cup of tea.
comments powered by Disqus
Follow RTT